Literature DB >> 22958930

FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.

S Haihua Chu1, Diane Heiser, Li Li, Ian Kaplan, Michael Collector, David Huso, Saul J Sharkis, Curt Civin, Don Small.   

Abstract

Internal tandem duplication (ITD) mutations within the FMS-like tyrosine kinase-3 (FLT3) render the receptor constitutively active driving proliferation and survival in leukemic blasts. Expression of FLT3-ITD from the endogenous promoter in a murine knockin model results in progenitor expansion and a myeloproliferative neoplasm. In this study, we show that this expansion begins with overproliferation within a compartment of normally quiescent long-term hematopoietic stem cells (LT-HSCs), which become rapidly depleted. This depletion is reversible upon treatment with the small molecule inhibitor Sorafenib, which also ablates the disease. Although the normal LT-HSC has been defined as FLT3(-) by flow cytometric detection, we demonstrate that FLT3 is capable of playing a role within this compartment by examining the effects of constitutively activated FLT3-ITD. This indicates an important link between stem cell quiescence/homeostasis and myeloproliferative disease while also giving novel insight into the emergence of FLT3-ITD mutations in the evolution of leukemic transformation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22958930      PMCID: PMC3725984          DOI: 10.1016/j.stem.2012.05.027

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  72 in total

1.  Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Authors:  D Auclair; D Miller; V Yatsula; W Pickett; C Carter; Y Chang; X Zhang; D Wilkie; A Burd; H Shi; S Rocks; R Gedrich; L Abriola; H Vasavada; M Lynch; J Dumas; P A Trail; S M Wilhelm
Journal:  Leukemia       Date:  2007-01-04       Impact factor: 11.528

Review 2.  Hematopoietic stem cell self-renewal.

Authors:  Omobolaji O Akala; Michael F Clarke
Journal:  Curr Opin Genet Dev       Date:  2006-08-17       Impact factor: 5.578

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.

Authors:  J Cloos; B F Goemans; C J Hess; J W van Oostveen; Q Waisfisz; S Corthals; D de Lange; N Boeckx; K Hählen; D Reinhardt; U Creutzig; G J Schuurhuis; Ch M Zwaan; G J L Kaspers
Journal:  Leukemia       Date:  2006-04-27       Impact factor: 11.528

5.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Authors:  Steven Knapper; Alan K Burnett; Tim Littlewood; W Jonathan Kell; Sam Agrawal; Raj Chopra; Richard Clark; Mark J Levis; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

6.  FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.

Authors:  Li Li; Obdulio Piloto; Kyu-Tae Kim; Zhaohui Ye; Ho Bao Nguyen; Xiaobing Yu; Mark Levis; Linzhao Cheng; Donald Small
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

7.  Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.

Authors:  Frances K Tong; Sue Chow; David Hedley
Journal:  Cytometry B Clin Cytom       Date:  2006-05       Impact factor: 3.058

8.  Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival.

Authors:  Yoshikane Kikushige; Goichi Yoshimoto; Toshihiro Miyamoto; Tadafumi Iino; Yasuo Mori; Hiromi Iwasaki; Hiroaki Niiro; Katsuto Takenaka; Koji Nagafuji; Mine Harada; Fumihiko Ishikawa; Koichi Akashi
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

9.  FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.

Authors:  Ronald Feitosa Pinheiro; Eloisa de Sá Moreira; Maria Regina Régis Silva; Fernando Lopes Alberto; Maria de Lourdes L F Chauffaille
Journal:  Cancer Genet Cytogenet       Date:  2008-06

10.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.

Authors:  Andrea Hoelbl; Boris Kovacic; Marc A Kerenyi; Olivia Simma; Wolfgang Warsch; Yongzhi Cui; Hartmut Beug; Lothar Hennighausen; Richard Moriggl; Veronika Sexl
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

View more
  59 in total

1.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Authors:  Alan H Shih; Yanwen Jiang; Cem Meydan; Kaitlyn Shank; Suveg Pandey; Laura Barreyro; Ileana Antony-Debre; Agnes Viale; Nicholas Socci; Yongming Sun; Alexander Robertson; Magali Cavatore; Elisa de Stanchina; Todd Hricik; Franck Rapaport; Brittany Woods; Chen Wei; Megan Hatlen; Muhamed Baljevic; Stephen D Nimer; Martin Tallman; Elisabeth Paietta; Luisa Cimmino; Iannis Aifantis; Ulrich Steidl; Chris Mason; Ari Melnick; Ross L Levine
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.

Authors:  Angeliki Thanasopoulou; Alexandar Tzankov; Juerg Schwaller
Journal:  Haematologica       Date:  2014-06-20       Impact factor: 9.941

3.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.

Authors:  Zhigang Cai; Jonathan J Kotzin; Baskar Ramdas; Sisi Chen; Sai Nelanuthala; Lakshmi Reddy Palam; Ruchi Pandey; Raghuveer Singh Mali; Yan Liu; Mark R Kelley; George Sandusky; Morvarid Mohseni; Adam Williams; Jorge Henao-Mejia; Reuben Kapur
Journal:  Cell Stem Cell       Date:  2018-12-06       Impact factor: 24.633

4.  ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells.

Authors:  Yiren Xiao; Zhiwu Jiang; Yin Li; Wei Ye; Bei Jia; Minjie Zhang; Yan Xu; Donghai Wu; Liangxue Lai; Yaoyu Chen; Yingjun Chang; Xiaojun Huang; Hudan Liu; Guoliang Qing; Pentao Liu; Yangqiu Li; Bing Xu; Mei Zhong; Yao Yao; Duanqing Pei; Peng Li
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

Review 5.  Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Authors:  Ya-Huei Kuo; Jing Qi; Guerry J Cook
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

6.  Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.

Authors:  Elodie Pronier; Robert L Bowman; Jihae Ahn; Jacob Glass; Cyriac Kandoth; Tiffany R Merlinsky; Justin T Whitfield; Benjamin H Durham; Antoine Gruet; Amritha Varshini Hanasoge Somasundara; Raajit Rampal; Ari Melnick; Richard P Koche; Barry S Taylor; Ross L Levine
Journal:  Blood       Date:  2018-07-31       Impact factor: 22.113

7.  MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice.

Authors:  M F Alemdehy; H W J de Looper; F G Kavelaars; M A Sanders; R Hoogenboezem; B Löwenberg; P J M Valk; I P Touw; S J Erkeland
Journal:  Leukemia       Date:  2016-06-04       Impact factor: 11.528

8.  Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.

Authors:  Lev M Kats; Markus Reschke; Riccardo Taulli; Olga Pozdnyakova; Kerri Burgess; Parul Bhargava; Kimberly Straley; Rahul Karnik; Alexander Meissner; Donald Small; Shinsan M Su; Katharine Yen; Jiangwen Zhang; Pier Paolo Pandolfi
Journal:  Cell Stem Cell       Date:  2014-01-16       Impact factor: 24.633

9.  Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells.

Authors:  Anna E Beaudin; Scott W Boyer; E Camilla Forsberg
Journal:  Exp Hematol       Date:  2013-12-11       Impact factor: 3.084

10.  Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.

Authors:  Manoj Garg; Yasunobu Nagata; Deepika Kanojia; Anand Mayakonda; Kenichi Yoshida; Sreya Haridas Keloth; Zhi Jiang Zang; Yusuke Okuno; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Ling-Wen Ding; Tamara Alpermann; Qiao-Yang Sun; De-Chen Lin; Wenwen Chien; Vikas Madan; Li-Zhen Liu; Kar-Tong Tan; Abhishek Sampath; Subhashree Venkatesan; Koiti Inokuchi; Satoshi Wakita; Hiroki Yamaguchi; Wee Joo Chng; Shirley-Kow Yin Kham; Allen Eng-Juh Yeoh; Masashi Sanada; Joanna Schiller; Karl-Anton Kreuzer; Steven M Kornblau; Hagop M Kantarjian; Torsten Haferlach; Michael Lill; Ming-Chung Kuo; Lee-Yung Shih; Igor-Wolfgang Blau; Olga Blau; Henry Yang; Seishi Ogawa; H Phillip Koeffler
Journal:  Blood       Date:  2015-10-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.